Treatment of levodopa‐induced motor complications
Identifieur interne : 002557 ( Main/Exploration ); précédent : 002556; suivant : 002558Treatment of levodopa‐induced motor complications
Auteurs : Fabrizio Stocchi [Italie] ; Michele Tagliati [États-Unis] ; C. Warren Olanow [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2008.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Adsorption, Advanced stage, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Catechol O-Methyltransferase Inhibitors, Complication, Deep Brain Stimulation, Dopamine Agonists (therapeutic use), Dopamine agonist, Drug Administration Schedule, Dyskinesia, Enzyme Inhibitors (therapeutic use), Fluctuations, Humans, Levodopa, Levodopa (adverse effects), Levodopa (pharmacokinetics), Levodopa (therapeutic use), Monoamine Oxidase Inhibitors (therapeutic use), Motor Activity (drug effects), Motor Activity (physiology), Movement Disorders (etiology), Movement Disorders (therapy), Nervous system diseases, Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson Disease (therapy), Parkinson disease, Safety, Treatment, advanced Parkinson's disease, dopamine agonists, dyskinesias, levodopa, motor fluctuations.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , pharmacokinetics : Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agonists, Enzyme Inhibitors, Levodopa, Monoamine Oxidase Inhibitors.
- drug effects : Motor Activity.
- drug therapy : Parkinson Disease.
- etiology : Movement Disorders.
- physiology : Motor Activity.
- physiopathology : Parkinson Disease.
- therapy : Movement Disorders, Parkinson Disease.
- Adsorption, Catechol O-Methyltransferase Inhibitors, Deep Brain Stimulation, Drug Administration Schedule, Humans, Safety.
Abstract
Chronic levodopa treatment for Parkinson's disease patients is frequently associated with the development of motor complications such as end‐of‐dose wearing‐off and dyskinesias. In this review, we provide an overview of the strategies available for dealing with these problems. Medical management includes manipulation of levodopa dosing to establish the optimum treatment schedule, improving levodopa absorption, catechol‐O‐methyl transferase‐inhibition (COMT), Monoamine oxidase‐B (MAO‐B) inhibition, dopaminergic agonists, amantadine, and continuous dopaminergic infusions. Surgical procedures and particularly deep brain stimulation are also reviewed. It should be noted that none of these treatments has been shown to provide anti‐parkinsonian efficacy that is greater than what can be achieved with levodopa. We highlight the importance of initiating therapy with a treatment strategy that reduces the risk that a Parkinson's disease patient will develop motor complications in the first place. Key Words: Advanced PD, dyskinesias, motor fluctuations, levodopa, dopamine agonists, COMT inhibitors, MAO‐B inhibitors. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22052
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000E33
- to stream Istex, to step Curation: 000E33
- to stream Istex, to step Checkpoint: 001113
- to stream PubMed, to step Corpus: 002049
- to stream PubMed, to step Curation: 002049
- to stream PubMed, to step Checkpoint: 002013
- to stream Ncbi, to step Merge: 002314
- to stream Ncbi, to step Curation: 002314
- to stream Ncbi, to step Checkpoint: 002314
- to stream Main, to step Merge: 003135
- to stream PascalFrancis, to step Corpus: 001125
- to stream PascalFrancis, to step Curation: 001B94
- to stream PascalFrancis, to step Checkpoint: 001034
- to stream Main, to step Merge: 003642
- to stream Main, to step Curation: 002557
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of levodopa‐induced motor complications</title><author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name></author><author><name sortKey="Tagliati, Michele" sort="Tagliati, Michele" uniqKey="Tagliati M" first="Michele" last="Tagliati">Michele Tagliati</name></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FB819C4FEC283B3BB9A75DE1B178F8C4EF044955</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.22052</idno><idno type="url">https://api.istex.fr/document/FB819C4FEC283B3BB9A75DE1B178F8C4EF044955/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000E33</idno><idno type="wicri:Area/Istex/Curation">000E33</idno><idno type="wicri:Area/Istex/Checkpoint">001113</idno><idno type="wicri:doubleKey">0885-3185:2008:Stocchi F:treatment:of:levodopa</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:18781681</idno><idno type="wicri:Area/PubMed/Corpus">002049</idno><idno type="wicri:Area/PubMed/Curation">002049</idno><idno type="wicri:Area/PubMed/Checkpoint">002013</idno><idno type="wicri:Area/Ncbi/Merge">002314</idno><idno type="wicri:Area/Ncbi/Curation">002314</idno><idno type="wicri:Area/Ncbi/Checkpoint">002314</idno><idno type="wicri:Area/Main/Merge">003135</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:08-0466180</idno><idno type="wicri:Area/PascalFrancis/Corpus">001125</idno><idno type="wicri:Area/PascalFrancis/Curation">001B94</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001034</idno><idno type="wicri:doubleKey">0885-3185:2008:Stocchi F:treatment:of:levodopa</idno><idno type="wicri:Area/Main/Merge">003642</idno><idno type="wicri:Area/Main/Curation">002557</idno><idno type="wicri:Area/Main/Exploration">002557</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment of levodopa‐induced motor complications</title><author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name><affiliation wicri:level="3"><country xml:lang="fr">Italie</country><wicri:regionArea>IRCCS San Raffaele, Via della Pisana 235, Roma</wicri:regionArea><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author><author><name sortKey="Tagliati, Michele" sort="Tagliati, Michele" uniqKey="Tagliati M" first="Michele" last="Tagliati">Michele Tagliati</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mount Sinai School of Medicine, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Mount Sinai School of Medicine, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008">2008</date><biblScope unit="vol">23</biblScope><biblScope unit="issue">S3</biblScope><biblScope unit="supplement">S3</biblScope><biblScope unit="page" from="S599">S599</biblScope><biblScope unit="page" to="S612">S612</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">FB819C4FEC283B3BB9A75DE1B178F8C4EF044955</idno><idno type="DOI">10.1002/mds.22052</idno><idno type="ArticleID">MDS22052</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adsorption</term><term>Advanced stage</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Catechol O-Methyltransferase Inhibitors</term><term>Complication</term><term>Deep Brain Stimulation</term><term>Dopamine Agonists (therapeutic use)</term><term>Dopamine agonist</term><term>Drug Administration Schedule</term><term>Dyskinesia</term><term>Enzyme Inhibitors (therapeutic use)</term><term>Fluctuations</term><term>Humans</term><term>Levodopa</term><term>Levodopa (adverse effects)</term><term>Levodopa (pharmacokinetics)</term><term>Levodopa (therapeutic use)</term><term>Monoamine Oxidase Inhibitors (therapeutic use)</term><term>Motor Activity (drug effects)</term><term>Motor Activity (physiology)</term><term>Movement Disorders (etiology)</term><term>Movement Disorders (therapy)</term><term>Nervous system diseases</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson Disease (therapy)</term><term>Parkinson disease</term><term>Safety</term><term>Treatment</term><term>advanced Parkinson's disease</term><term>dopamine agonists</term><term>dyskinesias</term><term>levodopa</term><term>motor fluctuations</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term><term>Enzyme Inhibitors</term><term>Levodopa</term><term>Monoamine Oxidase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Activity</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Movement Disorders</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Motor Activity</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Movement Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adsorption</term><term>Catechol O-Methyltransferase Inhibitors</term><term>Deep Brain Stimulation</term><term>Drug Administration Schedule</term><term>Humans</term><term>Safety</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Complication</term><term>Dyskinésie</term><term>Fluctuation</term><term>Lévodopa</term><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Stade avancé</term><term>Stimulant dopaminergique</term><term>Traitement</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Chronic levodopa treatment for Parkinson's disease patients is frequently associated with the development of motor complications such as end‐of‐dose wearing‐off and dyskinesias. In this review, we provide an overview of the strategies available for dealing with these problems. Medical management includes manipulation of levodopa dosing to establish the optimum treatment schedule, improving levodopa absorption, catechol‐O‐methyl transferase‐inhibition (COMT), Monoamine oxidase‐B (MAO‐B) inhibition, dopaminergic agonists, amantadine, and continuous dopaminergic infusions. Surgical procedures and particularly deep brain stimulation are also reviewed. It should be noted that none of these treatments has been shown to provide anti‐parkinsonian efficacy that is greater than what can be achieved with levodopa. We highlight the importance of initiating therapy with a treatment strategy that reduces the risk that a Parkinson's disease patient will develop motor complications in the first place. Key Words: Advanced PD, dyskinesias, motor fluctuations, levodopa, dopamine agonists, COMT inhibitors, MAO‐B inhibitors. © 2008 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Italie</li><li>États-Unis</li></country><region><li>Latium</li><li>État de New York</li></region><settlement><li>Rome</li></settlement></list><tree><country name="Italie"><region name="Latium"><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name></region></country><country name="États-Unis"><region name="État de New York"><name sortKey="Tagliati, Michele" sort="Tagliati, Michele" uniqKey="Tagliati M" first="Michele" last="Tagliati">Michele Tagliati</name></region><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002557 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002557 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:FB819C4FEC283B3BB9A75DE1B178F8C4EF044955
|texte= Treatment of levodopa‐induced motor complications
}}
| This area was generated with Dilib version V0.6.23. |  |